26,953 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Purchased by Decker Retirement Planning Inc.

Decker Retirement Planning Inc. purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 26,953 shares of the specialty pharmaceutical company's stock, valued at approximately $1,805,000. ANI Pharmaceuticals comprises about 1.1% of Decker Retirement Planning Inc.'s portfolio, making the stock its 14th biggest holding. Decker Retirement Planning Inc. owned about 0.12% of ANI Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Millennium Management LLC grew its holdings in shares of ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock worth $55,437,000 after acquiring an additional 473,097 shares during the period. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock valued at $37,906,000 after purchasing an additional 30,420 shares during the last quarter. Deep Track Capital LP lifted its stake in shares of ANI Pharmaceuticals by 28.6% in the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock worth $35,879,000 after purchasing an additional 144,214 shares during the period. Global Alpha Capital Management Ltd. lifted its stake in shares of ANI Pharmaceuticals by 16.4% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock worth $34,525,000 after purchasing an additional 88,100 shares during the period. Finally, William Blair Investment Management LLC boosted its holdings in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock worth $26,826,000 after buying an additional 10,440 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ANIP shares. Guggenheim reaffirmed a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday, May 12th. HC Wainwright restated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price target for the company. Wall Street Zen downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Finally, Truist Financial lifted their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research report on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Price Performance

ANIP traded down $1.69 on Tuesday, hitting $63.56. 321,916 shares of the company's stock traded hands, compared to its average volume of 324,905. The company's 50 day simple moving average is $64.25 and its 200-day simple moving average is $61.71. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $77.00. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -50.05 and a beta of 0.55.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The firm had revenue of $197.12 million for the quarter, compared to analysts' expectations of $179.75 million. During the same quarter last year, the business posted $0.82 earnings per share. The company's revenue for the quarter was up 43.4% compared to the same quarter last year. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the sale, the insider directly owned 107,317 shares of the company's stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Ori Gutwerg sold 881 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the sale, the senior vice president owned 89,897 shares in the company, valued at approximately $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,681 shares of company stock worth $346,854 in the last 90 days. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.